VEGF gene delivery for treatment of ischemic cardiovascular disease.
There are increasing numbers of patients with ischemic myocardial disease not amenable to traditional methods of revascularization. These patients may benefit from new research into the use of naturally occurring angiogenic compounds, such as vascular endothelial growth factor (VEGF) for re-establishing blood flow into regions of hibernating myocardium. Animal studies and human clinical trials evaluating VEGF demonstrate increases in myocardial perfusion after treatment, with some patients reporting improvement in anginal symptoms. Further research into the ideal form of VEGF therapy (protein, plasmid, or adenoviral) and delivery method (intracoronary, intramyocardial, or epicardial) seems justified.
Koransky
Mark L
ML
Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305-5175, USA.
Robbins
Robert C
RC
Blau
Helen M
HM
D000818:Animals; D002986:Clinical Trials as Topic; D016228:Endothelial Growth Factors / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D006801:Humans; D008222:Lymphokines / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000628:therapy*; D018919:Neovascularization, Physiologic / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors